Turning the corner on therapeutic cancer vaccines.

Hollingsworth RE, Jansen K. · 2019

Read Turning the corner on therapeutic cancer vaccines. by Hollingsworth RE, Jansen K. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6368616.txt.

Introduction

Hollingsworth and Jansen present a review in npj Vaccines on therapeutic cancer vaccines. Unlike preventive vaccines, these aim to treat existing cancers by training the immune system against tumor targets. Decades of attempts mostly failed, but the authors argue the field is turning a corner.

They review progress in three areas: choosing targets, vaccine technology, and reversing tumor immune suppression. Neoantigens from mutated proteins look specific and strongly immunogenic, though they demand personalized products. New platforms can raise balanced CD4 and CD8 T cell responses. Checkpoint drugs now offer partners that vaccines can combine with. The authors map the steps still needed for clinical success.

Catalog record

CREATORHollingsworth RE, Jansen K.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE75 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6368616

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Turning the corner on therapeutic cancer vaccines By Robert E Hollingsworth, Kathrin Jansen Published in: NPJ Vaccines DOI: 10.1038/s41541-019-0103-y ABSTRACT Abstract Recent advances in several areas are rekindling interest and enabling progress in the development of therapeutic cancer vaccines. These advances have been made in target selection, vaccine technology, and methods for reversing the immunosuppressive mechanisms exploited by cancers. Studies testing different tumor antigens have revealed target properties that yield high tumor versus normal cell specificity and adequate immunogenicity to affect clinical efficacy. A few tumor-associated antigens, normal host proteins that are abnormally expressed in cancer cells, have been demonstrated to serve as good targets for immunotherapies, although many do not possess the needed specificity or immunogenicity. Neoantigens, which arise from mutated proteins in cancer cells, are truly cancer-specific and can be highly immunogenic, though the vast majority are unique to each patient’s cancer and thus require development of personalized therapies. Lessons from previous cancer vaccine expeditions are teaching us the type and magnitude of immune responses needed, as well as vaccine technologies that can achieve these responses. For example, we are learning which vaccine approaches elicit the potent, balanced, and durable CD4 plus CD8 T cell expansion necessary for clinical efficacy. Exploration of interactions between the immune system and cancer has elucidated the adaptations that enable cancer cells to suppress and evade immune attack. This has led to breakthroughs in the development of new drugs, and, subsequently, to opportunities to combine these with cancer vaccines and dramatically increase patient responses. Here we review this recent progress, highlighting key steps that are bringing the promise of therapeutic cancer vaccines within reach. INTRODUCTION In terms of lives saved, vaccines have been the greatest triumphs of medicine. Since their first use by Edward Jenner and his contemporaries, vaccines have been developed to prevent numerous infectious diseases by training the immune system to rapidly and specifically destroy the offending pathogen thus preventing disease. The application of vaccines to cancer is an obvious extension of their utility, but attempts to achieve this have been a frustrating journey. An exception is the generation of prophylactic vaccines against hepatitis B virus (HBV) and human papillomavirus (HPV), which are causes of liver and cervical cancer, respectively.1,2 These prophylactic vaccines have been successful because they circumvent three major challenges facing the development of therapeutic cancer vaccines: (1) low immunogenicity; (2) established disease burden; and (3) the immunosuppressive tumor microenvironment. Much of the work on therapeutic cancer vaccines has taken aim at tumor-associated antigens (TAAs), which are aberrantly expressed self-antigens. Since high-affinity T cells recognizing self-antigens are eliminated during development by our immune system’s central and peripheral tolerance mechanisms, TAA-directed cancer vaccines face the challenge of activating any remaining, low affinity T cells. To work in the therapeutic setting, vaccine-stimulated immune responses must be able to kill millions or even billions of cancer cells. In addition, research over the last decade has revealed many potent immunosuppressive mechanisms that evolve during the course of cancer progression. In many cases, these mechanisms rely on abnormal activation of suppressors that under normal conditions are involved in dampening a natural immune response once a pathogen has been cleared or a wound has healed. Furthermore, the immune system in many cancer patients has been severely debilitated due to aging, the side effects of cancer therapies, or immune cell exhaustion.3–6 Our rapidly increasing understanding of the biology of these obstacles has led to new approaches that are enabling researchers to turn the corner toward development of effective therapeutic cancer vaccines. Much of this new knowledge emanates from studies aimed at dissecting the interactions of the immune system and cancer, including the elucidation of how cancers exploit T cell checkpoint mechanisms. The development of checkpoint inhibitors (CPIs), the first of which were anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies, represent a remarkable breakthrough in cancer medicine.7 Even so, these therapies are effective in only subsets of patients, and many patients who initially respond eventually relapse.8,9 Additional therapies are needed that can either elicit responses in patients who do not benefit from CPIs, or who do not benefit enough. Recent efforts focused on improving therapeutic cancer vaccine technology have been promising. In addition, intensive investigation into effective cancer vaccine targets has helped improve antigen selection, including more immunogenic and tumor-associated self-antigens, as well as neoantigens that harbor tumor-specific mutations. Combinations between CPIs and cancer vaccines are being tested as well. These efforts have brought about some encouraging clinical responses in patients. This review will summarize recent work and advances in target and antigen selection, cancer vaccine technologies, and combinations that may counteract the immunosuppressive tactics employed by tumors. CANCER VACCINE ANTIGENS The choice of antigen is the single most important component of cancer vaccine design. Ideally, the antigen should be expressed specifically by cancer cells (and not in normal cells), present on all cancer cells, necessary for cancer cell survival (such that the cancer cannot escape immune attack by downregulating the antigen), and highly immunogenic. Few if any antigens meet all of these criteria, yet there are several classes of antigens that have been employed in cancer vaccines (Fig. 1). [Figure: Therapeutic cancer vaccine target types. Targets for tumor vaccines fall into two general classes: tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs). TAAs are self-antigens that are either preferentially or abnormally expressed in tumor cells, but may be expressed at some level in normal cells as well. As self-antigens, T cells that bind with high affinity to TAAs are typically deleted from the immune repertoire by central and peripheral tolerance mechanisms, and thus a cancer vaccine using these antigens must be potent enough to “break tolerance.” TSAs, comprised of antigens expressed by oncoviruses and neoantigens encoded by cancer mutations, are truly tumor-specific and as such high-affinity T cells may be present and strongly activated by these antigens. Although individual oncoviral antigens are expressed in specific tumor types (e.g., the HPV E6 and E7 antigens in cervical cancer), this occurs in many patients. Similarly, neoantigens encoded by oncogenic driver mutations may be prevalent across patients and tumor types, and hence are referred to as shared neoantigens. The majority of neoantigens are unique to individual patients’ tumors (private neoantigens), and thus require generation of a personalized therapy] Tumor-associated antigens To date, most cancer vaccines have targeted TAAs, which are self-proteins that are abnormally expressed by cancer cells. TAAs include: cancer/germline antigens (also known as cancer/testis or CT antigens), which are normally expressed only in immune privileged germline cells (e.g., MAGE-A1, MAGE-A3, and NY-ESO-1);10–14 cell lineage differentiation antigens, which are normally not expressed in adult tissue (e.g., tyrosinase, gp100, MART-1, prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP));15–19 and antigens that are overexpressed in cancer cells (e.g., hTERT, HER2, mesothelin, and MUC-1).20–23 Several hurdles are associated with developing vaccines against TAAs. First, as self-antigens, B cells and T cells that strongly recognize these antigens may have been removed from the immune repertoire by central and peripheral tolerance. Thus, a cancer vaccine must “break tolerance” by stimulating the low affinity or rare TAA-reactive T cells that remain.24 Strong adjuvants, co-stimulators, and repeated vaccination have been used to amplify the activation and expansion of self-antigen-reactive T cells,25 and this is particularly important for low-affinity

Read the complete text